Refine by
Tumor Targeting Suppliers & Manufacturers
69 companies found
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...
TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
Glycosylation is a post-translational modification that occurs inside the cell and results in the addition of sugar motifs, “glycans”, to proteins and lipids that are, in most cases, destined for the cell surface. These glycan structures ...
based inLyon, FRANCE
Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugates (ADCs). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the ...
Most of the challenges of ADCs are linked to the hydrophobicity of the cytotoxic drugs used, which degrade the pharmacological properties of the antibody when attached to ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Induced pluripotent stem cells (iPSCs) are established by introducing several factors to somatic cells such as skin cells. iPSCs can differentiate into the cells of a various tissues or organs (pluripotency) and grow indefinitely (proliferation). ...
based inSalt Lake City, UTAH (USA)
PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established global distribution. PYREXAR Hyperthermia treatments increase the ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
Target validation is an essential and critical phase of the drug discovery process. This is a crucial step before starting to develop a treatment based on a targeted protein that has been identified to play a role in the disease. The target ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
based inSaint-Herblain Cedex, FRANCE
Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments. The growing medical need and the lack of effective treatments for bone tumors gave rise to Atlanthera in 2011, a drug discovery company focused on bone ...
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for novel small molecule PD-L1 ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inBerkeley, CALIFORNIA (USA)
SonALAsense’s ALA sonodynamic therapy (SDT) is well differentiated from the use of other forms of therapy which have been used for GBM or rGBM. Our use of a MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both ...
We are committed to providing hope in the face of despair with a unique proprietary non-invasive drug-device combination therapy, ALA Sonodynamic Therapy (SDT), for the treatment of recurrent glioblastoma multiforme (rGBM). ...